Dechert Advises vTv Therapeutics on US$80 Million PIPE With Leading Healthcare Institutional Investors and T1D Fund

Dechert advised vTv Therapeutics Inc. on a US$80 million private placement in public equity (PIPE) financing with leading healthcare institutional investors including existing investors, Samsara BioCapital, another life sciences-focused institutional investor and the T1D Fund: A Breakthrough T1D Venture, LLC, as well as new investors, including Trails Edge Capital Partners and Invus.

The financing will fund the ongoing development of cadisegliatin, including CATT1, a trial assessing its potential to reduce the frequency of level 2 and 3 hypoglycemic events and improve glycemic control in people with type 1 diabetes. vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases.

The Dechert team that advised vTv was led by corporate and life sciences partner David S. Rosenthal and included associates Taylor Stevens, Anjanaye Jariwala and Abigail T. Ferraioli.

About Dechert

Dechert is the law firm that helps business leaders lead.

For more than 150 years, we have advised clients on critical issues – from high-stakes litigation to first-in-market transaction structures and complex regulatory matters. Our nearly 1,000 lawyers in commercial centers worldwide are immersed in the key sectors we serve – financial services, private capital, real estate, life sciences and technology.

Dechert delivers unwavering partnership so our clients can achieve unprecedented results.